Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts Fibrocaps MAA for review

Nov. 29, 2013

EMA grants accelerated assessment to faldaprevir

Nov. 27, 2013

Celgene receives positive CHMP opinion for Abraxane in combination with gemcitabine

Nov. 26, 2013

Ariad Pharmaceuticals obtains positive CHMP opinion on the continued use of Iclusig

Nov. 26, 2013

Dimethyl fumarate in Tecfidera qualifies as new active substance in Europe

Nov. 25, 2013

Deltyba obtains European CHMP recommendation upon re-examination

Nov. 25, 2013

Positive CHMP opinion for cetuximab in RAS wild-type metastatic colorectal cancer

Nov. 25, 2013

EMA's CHMP supports approval of Xigduo for type 2 diabetes

Nov. 25, 2013

European CHMP recommends approval of Sovaldi

Nov. 25, 2013

DengueCide receives EMA orphan drug designation

Nov. 12, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...